Introduction: Prior to registration, no clinical trial evaluating safety and tolerability of Zolafren® (Adamed Sp. z o.o., Czosnów, Poland), a generic olanzapine formulation, had been performed. Therefore, the aim of this post-authorization safety study (PASS) was to evaluate the safety and tolerability of Zolafren in patients with bipolar disorder (BD). Methods: Adverse events (AEs) associated with the use of Zolafren were recorded in a PASS, in an open-label, non-randomized, multicenter observational study involving 20,698 outpatients with BD. Results: Zolafren was used in both monotherapy (82.8%) and polytherapy (17.2%) at a mean dose of 12.1 ± 4.2 mg. The most commonly used formulation was coated tablets (70.9%). Orally dissolving tablets (19.7%) and hard capsules (9.4%) were less commonly used. During a period of 171 ± 47 days of exposure to Zolafren, 5883 AEs were reported in 2138 patients (10.3% of the study population). None of the reported AEs were severe. Zolafren-associated AEs were the reason for discontinuation in 43 patients and the reason for dose reduction in a further 762 patients. The most common AE was weight gain (by 1.6 ± 3.3 kg) which was considered unrelated to the dose of Zolafren. During follow-up, the percentage of patients with very good tolerance with Zolafren increased from 44.4% to 59.8%. The percentage of patients who had confidence in Zolafren also increased. Conclusion: The results of this PASS support the safety of Zolafren use and indicate a high tolerance in patients treated for BD. Funding: Adamed Sp. z o.o., Czosnów, Poland.
CITATION STYLE
Chudek, J., Olszanecka-Glinianowicz, M., Almgren-Rachtan, A., & Gabryelewicz, T. (2015). Evaluation of the Safety Profile of Zolafren®, a Generic Olanzapine Formulation, in Patients with Bipolar Disorder: A Post-Authorization Safety Study. Advances in Therapy, 32(5), 418–428. https://doi.org/10.1007/s12325-015-0210-8
Mendeley helps you to discover research relevant for your work.